The antifungal susceptibility of Candida albicans isolated from HIV/AIDS patients

Sri Rezeki, Siti Aliyah Pradono, Gus Permana Subita, Yeva Rosana, S. Sunnati, Basri A. Gani

Abstract views = 630 times | downloads = 294 times


Background: Candida albicans was found to be dominant in patients with human immunodeficiency virus / acquired immunodeficiency syndrome (HIV/AIDS). The antifungals fluconazole, ketoconazole, and nystatin were used as oral candidiasis therapy for HIV/AIDS, each of which has differing susceptibility in oral candidiasis therapy. Purpose: The present study aimed to evaluate the susceptibility and antifungal resistance to oral C. albicans in HIV/AIDS patients. Methods: The subjects followed the universal precaution principles. Oral Candida species were isolated from the saliva of 98 HIV/AIDS subjects. Identification of Candida species was carried out by the mycobiotic agar of API 20 C Aux system. Susceptibility and resistance antifungal tests on the Candida species were performed using a Fungus ATB Kit. Results: Candida albicans was the most dominant species found from 98 subjects (95%). The rest were other Candida species. There are 41 subjects (42%) with a history of oral candidiasis, and 57 subjects (58%) without. The history of those who used antifungals were: nystatin = 60 subjects (61%), fluconazole = 39 subjects (40%), and ketoconazole = two subjects (2%). These antifungals have a susceptibility above 80% against C. albicans, except the nystatin group (79%) (p>0.05; 0.628), but fluconazole has a strong correlation (r=0.820) to susceptibility, susceptibility-dependent dose, and resistance. Conclusion: Candida albicans was dominant in the saliva of HIV/AIDS patients. This fungus was effectively treated by fluconazole, ketoconazole and nystatin. These antifungals had a high susceptibility at ≤ 8 μg/mL to C. albicans.


antifungal; Candida albicans; HIV/AIDS; susceptibility and resistance

Full Text:



Rahmawati M. Penangulangan HIV/AIDS di Indonesia dalam ancaman RKUHP: Proyeksi dampak kriminalisasi perilaku beresiko transmisi HIV/AIDS dalam RKUHP terhadap penanggulangan HIV/AIDS di Indonesia. Jakarta: Institute for Criminal Justice Reform; 2019. p. 7–8.

Anwar KP, Malik A, Subhan KH. Profile of candidiasis in HIV infected patients. Iran J Microbiol. 2012; 4(4): 204–9.

Wilson D. Candida albicans. Trends Microbiol. 2019; 27(2): 188–9.

Thompson GR, Patel PK, Kirkpatrick WR, Westbrook SD, Berg D, Erlandsen J, Redding SW, Patterson TF. Oropharyngeal candidiasis in the era of antiretroviral therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010; 109(4): 488–95.

Mulu A, Kassu A, Anagaw B, Moges B, Gelaw A, Alemayehu M, Belyhun Y, Biadglegne F, Hurissa Z, Moges F, Isogai E. Frequent detection of ‘azole’ resistant Candida species among late presenting AIDS patients in northwest Ethiopia. BMC Infect Dis. 2013; 13: 82.

Rodrigues CF, Rodrigues ME, Henriques M. Candida sp. Infections in Patients with Diabetes Mellitus. J Clin Med. 2019; 8(1): 76.

Katiraee F, Teifoori F, Soltani M. Emergence of azole-resistant Candida species in AIDS patients with oropharyngeal candidiasis in Iran. Curr Med Mycol. 2015; 1(3): 11–6.

Mohamadi J, Motaghi M, Panahi J, Havasian MR, Delpisheh A, Azizian M, Pakzad I. Anti-fungal resistance in candida isolated from oral and diaper rash candidiasis in neonates. Bioinformation. 2014; 10(11): 667–70.

Monroy-Pérez E, Paniagua-Contreras GL, Rodríguez-Purata P, Vaca-Paniagua F, Vázquez-Villaseñor M, Díaz-Velásquez C, Uribe-García A, Vaca S. High Virulence and Antifungal Resistance in Clinical Strains of Candida albicans. Can J Infect Dis Med Microbiol = J Can des Mal Infect la Microbiol medicale. 2016; 2016: 5930489.

Hasim S, Coleman JJ. Targeting the fungal cell wall: current therapies and implications for development of alternative antifungal agents. Future Med Chem. 2019; 11(8): 869–83.

Tellier R, Li Y, Cowling BJ, Tang JW. Recognition of aerosol transmission of infectious agents: a commentary. BMC Infect Dis. 2019; 19: 101.

Lozano Moraga CP, Rodríguez Martínez GA, Lefimil Puente CA, Morales Bozo IC, Urzúa Orellana BR. Prevalence of Candida albicans and carriage of Candida non-albicans in the saliva of preschool children, according to their caries status. Acta Odontol Scand. 2017; 75(1): 30–5.

Arastehfar A, Daneshnia F, Kord M, Roudbary M, Zarrinfar H, Fang W, Hashemi SJ, Najafzadeh MJ, Khodavaisy S, Pan W, Liao W, Badali H, Rezaie S, Zomorodian K, Hagen F, Boekhout T. Comparison of 21-Plex PCR and API 20C AUX, MALDI-TOF MS, and rDNA Sequencing for a Wide Range of Clinically Isolated Yeast Species: Improved Identification by Combining 21-Plex PCR and API 20C AUX as an Alternative Strategy for Developing Countries. Front Cell Infect Microbiol. 2019; 9: 21.

Zhang L, Wang H, Xiao M, Kudinha T, Mao L-L, Zhao H-R, Kong F, Xu Y-C. The widely used ATB FUNGUS 3 automated readings in China and its misleading high MICs of Candida spp. to azoles: challenges for developing countries’ clinical microbiology labs. PLoS One. 2014; 9(12): e114004.

Patil S, Majumdar B, Sarode SC, Sarode GS, Awan KH. Oropharyngeal Candidosis in HIV-infected patients-An update. Front Microbiol. 2018; 9: 980.

Glick SN, Morris M, Foxman B, Aral SO, Manhart LE, Holmes KK, Golden MR. A comparison of sexual behavior patterns among men who have sex with men and heterosexual men and women. J Acquir Immune Defic Syndr. 2012; 60(1): 83–90.

Berkow EL, Lockhart SR. Fluconazole resistance in Candida species: a current perspective. Infect Drug Resist. 2017; 10: 237–45.

Garcia-Cuesta C, Sarrion-Pérez M-G, Bagán J V. Current treatment of oral candidiasis: A literature review. J Clin Exp Dent. 2014; 6(5): e576-82.

Williams D, Lewis M. Pathogenesis and treatment of oral candidosis. J Oral Microbiol. 2011; 3: 1–11.

Gaitán-Cepeda LA, Sánchez-Vargas O, Castillo N. Prevalence of oral candidiasis in HIV/AIDS children in highly active antiretroviral therapy era. A literature analysis. Int J STD AIDS. 2015; 26(9): 625–32.

Maheshwari M, Kaur R, Chadha S. Candida species prevalence profile in HIV seropositive patients from a major tertiary care hospital in New Delhi, India. J Pathog. 2016; 2016: 6204804.

Brito GNB, Inocêncio AC, Querido SMR, Jorge AOC, Koga-Ito CY. In vitro antifungal susceptibility of Candida spp. oral isolates from HIV-positive patients and control individuals. Braz Oral Res. 2011; 25(1): 28–33.

Butts A, Reitler P, Nishimoto AT, DeJarnette C, Estredge LR, Peters TL, Veve MP, Rogers PD, Palmer GE. A systematic screen reveals a diverse collection of medications that induce antifungal resistance in Candida species. Antimicrob Agents Chemother. 2019; 63(5): e00054-19.

Patil S, Rao RS, Majumdar B, Anil S. Clinical appearance of oral Candida infection and therapeutic strategies. Front Microbiol. 2015; 6: 1391.

Whaley SG, Berkow EL, Rybak JM, Nishimoto AT, Barker KS, Rogers PD. Azole antifungal resistance in Candida albicans and emerging non-albicans Candida species. Front Microbiol. 2016; 7: 2173.


  • There are currently no refbacks.

View My Stats